IVIG is given after plasmapheresis because plasmapheresis strips the blood of both harmful and protective antibodies, and IVIG helps replenish immune function while also providing its own therapeutic effects. The two treatments work on different timelines and through different mechanisms, making them complementary rather than redundant. Understanding why they’re paired, and in this specific order, comes down to basic biology and practical timing.
What Each Treatment Does
Plasmapheresis (also called plasma exchange or PLEX) physically removes plasma from your blood, filters out the harmful components, and returns the cleaned blood to your body. It pulls out pathogenic antibodies, immune complexes, and inflammatory signaling molecules. This makes it effective for rapid control during acute flare-ups of autoimmune and inflammatory conditions. The downside is that it’s indiscriminate: it removes the bad actors along with your normal, protective immunoglobulins. A course of plasmapheresis reduces levels of all major antibody types (IgG, IgM, IgA, and IgE) by more than 40%.
IVIG works through slower, more complex immune pathways. It modulates how immune cells communicate, dampens overactive complement responses, and helps regulate both T-cell and B-cell behavior. These effects take days to fully develop, which is why IVIG alone isn’t always fast enough during a crisis.
Why the Order Matters
If IVIG were given before plasmapheresis, the next plasma exchange session would simply wash it out. IVIG is made of concentrated immunoglobulin G, exactly the kind of protein plasmapheresis is designed to remove. Giving it first would be expensive and pointless.
By reversing the order, plasmapheresis clears the slate first, removing the disease-driving antibodies as quickly as possible. Then IVIG steps in to do two things simultaneously: replace the protective antibodies that were lost during the exchange and begin its own longer-acting immune regulation. This sequencing lets each treatment do its job without canceling out the other.
Replacing What Plasmapheresis Takes Away
After a course of plasmapheresis, your immune system is temporarily depleted. That 40%-plus drop in immunoglobulin levels leaves you more vulnerable to infections and without the normal immune surveillance your body relies on. IVIG delivers a concentrated dose of pooled antibodies from thousands of donors, restoring a functional baseline while your body rebuilds its own supply.
There has been longstanding debate about whether plasmapheresis triggers an “overshoot,” where the body responds to the sudden antibody loss by ramping up production of both normal and pathogenic antibodies beyond their original levels. Some animal studies and small patient studies have reported this rebound effect. However, a study in myasthenia gravis patients found no consistent overshoot in immunoglobulin levels and no clear evidence of accelerated autoantibody production after plasma exchange. The ratio of disease-causing antibodies to total IgG remained stable. So while rebound is a theoretical concern, the primary reason for giving IVIG afterward is replacement and immune modulation, not necessarily preventing a surge.
Conditions Where This Combination Is Used
This sequential approach shows up across several conditions. In myasthenia gravis, both IVIG and plasmapheresis are effective on their own. A comparative trial found that 69% of patients improved on IVIG and 65% improved on plasmapheresis at two weeks, with no statistically significant difference in overall outcomes. However, plasmapheresis tends to work faster, with clinical differences visible at about seven days versus a slower onset with IVIG alone. Combining them in sequence offers the speed of plasmapheresis with the sustained immune modulation of IVIG.
In Guillain-Barré syndrome, the pairing follows similar logic. Plasmapheresis rapidly reduces the autoimmune attack on peripheral nerves, and IVIG supports ongoing immune regulation afterward.
In organ transplantation, particularly lung transplants, the combination is used to treat antibody-mediated rejection. One standardized protocol involves plasma exchange every other day, with an IVIG infusion of 100 mg/kg given after each session. After completing five plasmapheresis sessions, a larger loading dose of 500 mg/kg is administered over three separate doses. This stepwise approach gradually shifts from aggressive antibody removal to sustained immune suppression.
Typical Dosing Patterns
IVIG doses in this context vary depending on the condition and the treatment phase. During active plasmapheresis cycles, smaller maintenance doses (around 100 mg/kg) are common after each exchange session. These replace what was lost without overwhelming the system before the next exchange. Once the plasmapheresis course is complete, larger doses are typically given, often totaling 1 to 2 g/kg spread over several days. In the lung transplant protocol mentioned above, patients received a median of four IVIG doses at 1 g/kg per admission.
The timing between the last plasmapheresis session and the first IVIG dose doesn’t appear to follow a strict universal rule. Research on Guillain-Barré patients found no correlation between the interval separating the two treatments and short-term outcomes, suggesting that the sequence itself matters more than hitting a precise hour window.
Risks of the Combined Approach
Both treatments independently raise the risk of venous blood clots. A large case-crossover study examining 1.9 million hospital admissions found that the odds of venous thromboembolism within 30 days were roughly 3.3 times higher after IVIG and 4.3 times higher after plasmapheresis, compared to periods without treatment. Neither therapy was linked to increased heart attack or stroke risk. When the two are used together, the clot risk is something clinical teams monitor closely, particularly in patients who are already immobile or have other clotting risk factors.
IVIG can also cause headaches, fever, and chills during infusion, and in rare cases it places stress on the kidneys. Plasmapheresis carries its own set of issues, including low blood pressure during sessions, electrolyte shifts, and risks associated with the central line used for blood access. Combining the treatments means navigating both sets of side effects, which is one reason this approach is generally reserved for severe or treatment-resistant disease rather than mild cases.